In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Predictors of a reduction in blood pressure after catheter-based renal sympathetic denervation

Session Poster Session 3

Speaker Gintare Neverauskaite Piliponiene

Congress : Acute Cardiovascular Care 2019

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Interventional Cardiology - Other
  • Session type : Poster Session
  • FP Number : P823

Authors : G Neverauskaite Piliponiene (Vilnius,LT), A Berukstis (Vilnius,LT), A Laucevicius (Vilnius,LT)


G Neverauskaite Piliponiene1 , A Berukstis2 , A Laucevicius2 , 1Vilnius University, Faculty of Medicine - Vilnius - Lithuania , 2Vilnius University, Clinic of Heart and Vessel Diseases, Institute of Clinical Medicine Faculty of Medicine - Vilnius - Lithuania ,


Background/introduction: Renal sympathetic denervation (RSD) is a new method in treatment of resistant hypertension (RH). It is not clear who benefit most from the treatment with catheter-based RSD and why some patients have no changes in their blood pressures after the procedure.
Purpose: To identify predictors for BP variations in RH patients after RSD and evaluate BP changes.
Methods: A prospective cohort study of 73 patients with RH who had RSD performed from 2012 to 2017. Patients’ office and 24-hour blood pressure were measured before the procedure and 1, 3, 6 months after the RSD. Linear mixed model was used to assess predictors for office and 24-hour blood pressure change 6 months after RSD. The model had incorporated factors such as age, sex, body mass index (BMI), number of renal ablations (RA) and baseline BP.
Results: Blood pressure 6 month after procedure dropped from 190/107 ±22/13 to 156/90 ±25/12 mm Hg (p<0.001). 24-hour ambulatory blood pressure at month 6 dropped from 163/97 ±18/14 to 149/90 ±20/10 mm Hg (p<0.001).Predictors for office systolic BP reduction after 6 months were age and baseline systolic BP. More rapid BP reduction was observed in younger patients (<61 vs. >61), by average of -21.95 mm Hg, p=0.0008. Baseline office systolic BP group >210 mm Hg showed more rapid downward over time than group =170 mmHg, by average of -34,11 mm Hg, p<0.0005. The only predictor for diastolic office BP reduction 6 months was baseline BP. Patients diastolic office baseline BP group >115 mm Hg showed a significant greater reduction than BP group =100 mm Hg at baseline, by average of -17.15 mm Hg, p=0.0001. Higher reduction in 24-hour systolic BP after 6 months was noticed for women, by average of -11.34 mm Hg, p=0.0128. Larger 24-hour systolic BP reduction was noticed in younger patients (<61 vs. >61), by average of -20.09 mm Hg, p<0.001. Higher 24-hour baseline systolic BP (>170 mm Hg) showed a greater BP reduction after 6 months as compared with =170 mm Hg baseline 24-hour systolic BP, by average of -16.33 mm Hg, (p=0.0026). Greater 24-hour baseline diastolic BP reduction after 6 months was seen in patients with diastolic BP >100 mm Hg, average -11.78 mm Hg, p=0.0008. Patients aged < 61 sustained a more rapid drop in 24-hour diastolic BP than those aged >61, by average of -11,91 mmHg, (p=0.003).No significant difference in any BP after 6 months was found between patients with a different number of ablations and BMIs.
Conclusions: Based on patient randomisation for the catheter-based RSD procedure, the best results might be expected in patients with higher baseline BP values and younger age. A more considerable reduction in BP among patients under 61 was noticed.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are